Sign in to continue:

Wednesday, March 4th, 2026

Ultra Clean Holdings, Inc. Issues $600 Million 0.00% Convertible Senior Notes Due 2031 – Key Details from 8-K Filing





Ultra Clean Holdings, Inc. Issues \$600 Million Convertible Notes

Ultra Clean Holdings, Inc. Announces \$600 Million Convertible Notes Offering and Key Material Agreements

Key Points from the Form 8-K Filing

  • Ultra Clean Holdings, Inc. (“UCT”) has issued \$600,000,000 principal amount of convertible senior notes due 2029.
  • The notes were issued on March 3, 2026 and are convertible into UCT common stock, subject to anti-dilution adjustments.
  • Maximum of 10,089,120 shares could be issued upon conversion, based on an initial conversion rate of 16.8152 shares per \$1,000 principal amount.
  • The notes do not bear regular interest; however, “special interest” and “additional interest” may accrue under certain circumstances.
  • The offering was made in reliance on Section 4(a)(2) of the Securities Act, and initial resale was limited to “qualified institutional buyers” under Rule 144A.
  • Underlying shares issued upon conversion will rely on Section 3(a)(9), meaning no public offering is involved.
  • The notes are listed on The Nasdaq Global Market under the trading symbol UCTT.
  • Shareholders have rights to require repurchase of the notes in a “Fundamental Change,” including change of control, liquidation, business combination, or delisting events.
  • UCT has entered into “Capped Call Transactions” to reduce dilution upon conversion.
  • There is no sinking fund required for the notes.
  • Emerging Growth Company status: UCT is not an emerging growth company.
  • The company is required to file Exchange Act reports, and failure to do so could result in additional interest on the notes.
  • All material agreements and the form of the notes are included in Exhibits 4.1 and 4.2.

Details Investors and Shareholders Must Know

Convertible Notes Details & Potential Dilution

The issuance of \$600 million in convertible senior notes introduces a substantial new convertible security into UCT’s capital structure. These notes can be converted into common stock at an initial conversion rate of 16.8152 shares per \$1,000 principal, meaning that if all notes are converted, up to 10,089,120 new shares could be issued. This represents a potentially significant dilution for existing shareholders, especially if UCT’s share price rises above the conversion price.

The anti-dilution provisions mean that conversion rates can be adjusted in the event of stock splits, dividends, or other corporate actions. Investors should be aware that these adjustments can impact the actual number of shares issued and thus their percentage ownership.

Repurchase Rights on Fundamental Change

If UCT undergoes a “Fundamental Change” (such as a change of control, merger, liquidation, or delisting from Nasdaq), holders of the notes can require the company to repurchase their notes in cash at the principal amount plus any accrued special or additional interest. This provision protects noteholders but could create a significant cash outflow or affect UCT’s liquidity if triggered, which may impact share price.

Capped Call Transactions

UCT has entered into capped call transactions intended to mitigate dilution and/or offset potential increases in the conversion value of the notes. These instruments serve to reduce the impact on earnings per share and limit the number of shares that may be issued upon conversion. This is generally positive for shareholders, as it helps preserve value and reduces dilution risk.

Reporting Requirements and Additional Interest

The company is required to file certain SEC reports. If it fails to timely file required reports (other than Form 8-K) or if the notes are not “freely tradable,” additional interest may accrue on the notes. This clause gives investors confidence in ongoing transparency but also presents a risk that the company could incur added costs if it fails to comply with reporting obligations.

Unregistered Sales and Qualified Institutional Buyers

The notes were sold in transactions not involving any public offering. Initial purchasers could only resell to qualified institutional buyers, which may limit liquidity for the notes but also signals a targeted, sophisticated investor base.

Shareholder and Price Sensitivity

  • The large potential dilution from conversion of the notes is a material risk and could affect share price if conversion is likely.
  • Fundamental Change provisions, especially in the event of M&A or delisting, may trigger significant cash obligations for UCT.
  • Capped call transactions help reduce dilution and may support share price.
  • Failure to comply with SEC reporting could result in additional interest costs and possibly signal governance issues.
  • Any significant change in capital structure, liquidity, or management action related to these notes could be price sensitive.

Summary

Ultra Clean Holdings, Inc.’s issuance of \$600 million in convertible notes is a significant capital markets event. The potential dilution, repurchase rights on fundamental changes, and capped call transactions are all material for shareholders and could impact share value. Investors should closely monitor the company’s compliance with reporting requirements and any corporate actions that could trigger conversion or repurchase provisions.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review official filings and consult with financial advisors before making any investment decisions. The information herein is based on Form 8-K filings and associated exhibits and may be subject to change or interpretation.




View Ultra Clean Holdings, Inc. Historical chart here



Astellas and Vir Biotechnology Announce $335M Global Collaboration to Advance VIR-5500 for Prostate Cancer Treatment

Astellas and Vir Biotechnology Enter Global Strategic Collaboration to Advance VIR-5500 for Prostate Cancer Treatment Key Points for Investors Major Collaboration: Astellas Pharma Inc. and Vir Biotechnology, Inc. have announced a global strategic collaboration...

Apogee Therapeutics 2025 Annual Report: Pipeline Overview, Strategy, and Clinical Progress in Inflammatory and Immunology Markets

Key Highlights from Apogee Therapeutics, Inc. 2025 Annual Report: Strategic Developments and Financial Position Introduction Apogee Therapeutics, Inc. (Nasdaq: APGE) has released its Annual Report for the fiscal year ended December 31, 2025. This...

Silo Pharma Announces $1 Million Share Buyback Program to Enhance Shareholder Value

Silo Pharma Announces Share Buyback Program – Investor Summary Silo Pharma Announces \$1 Million Share Buyback Program Sarasota, FL – February 23, 2026: Silo Pharma, Inc. (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury...

   Ad